Jiangsu Hengrui Medicine
600276.SS
#494
Rank
C$58.10 B
Marketcap
$9.11
Share price
-0.62%
Change (1 day)
9.88%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): C$1.12 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are C$3.63 Billion. In 2023 the company made an earning of C$0.94 Billion, an increase over its 2022 earnings that were of C$0.85 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) C$1.12 B18.58%
2023 C$0.94 B11.4%
2022 C$0.85 B-13.65%
2021 C$0.98 B-34.21%
2020 C$1.49 B15.95%
2019 C$1.29 B33.03%
2018 C$0.97 B20.89%
2017 C$0.80 B23.89%
2016 C$0.64 B11.21%
2015 C$0.58 B39.5%
2014 C$0.41 B20.61%
2013 C$0.34 B11.46%
2012 C$0.31 B29.7%
2011 C$0.23 B31.16%
2010 C$0.18 B27.92%
2009 C$0.14 B5.8%
2008 C$0.13 B79.95%
2007 C$75.05 M32.89%
2006 C$56.48 M38.19%
2005 C$40.87 M21.56%
2004 C$33.62 M13.95%
2003 C$29.5 M38.06%
2002 C$21.37 M